Carcinoma
Drug research and approvals for carcinoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 4,641 studies of carcinoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 238 drug trials for it since 2013, FDA has 54 approved and 182 open orphan designations naming it, and the EU has 68 authorised medicines for it.
- Recruiting worldwide: 4,641
- Trials authorized in Canada: 238
- FDA orphan approvals: 54
- EU medicines: 68
- Chemotherapy-Minimized Blank Microsphere Transarterial Embolization (BMS-TACE) Plus Low-Dose Lenvatinib, Iparomlimab…NCT07951021 · Phase 2 · Sun Yat-sen University · starts Oct 15, 2026
- Ultra-hypofractionated radiotHErapy and Concomitant Oral RelugOlix for Treatment of Intermediate Risk Prostate Cancer.NCT07947745 · Not applicable · Azienda Ospedaliero-Universitaria Careggi · starts Jun 18, 2025
- Chemotherapy-Minimized Blank Microsphere Transarterial Embolization (BMS-TACE) in Hepatocellular Carcinoma Resistant to…NCT07947342 · Phase 2 · Sun Yat-sen University · starts Oct 20, 2026
- Compressive Dressing and Pharyngocutaneous Fistula After Primary Total LaryngectomyNCT07949526 · Not reported · IRCCS San Raffaele · starts May 5, 2025
- Histotripsy for Renal Cell CarcinomaNCT07943143 · Not applicable · The University of Hong Kong · starts Oct 13, 2026
- A Multicenter, Open-label, Phase 1/1b, Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of…NCT07940881 · Phase 1 · SystImmune Inc. · starts Aug 24, 2026
- Combinations With Lenvatinib in Patients With Metastatic Chromophobe Renal Cell Carcinoma.NCT07937553 · Phase 2 · Kidney Cancer Research Bureau · starts Aug 15, 2025
- Characterisation of Immunological and Molecular Changes Evolving in Patients Undergoing Radiotherapy (CHIMERA)NCT07938385 · Not reported · Royal Marsden NHS Foundation Trust · starts May 20, 2022
- Evaluating Photodynamic Therapy Used to Treat Cutaneous Squamous Cell Carcinoma in Situ (isSCC) on the Face, Upper…NCT07931664 · Phase 2 · The Center for Clinical and Cosmetic Research · starts Nov 25, 2025
Approved 24 of 64
- SorafenibHepatocellular cancer · Serine/threonine-protein kinase RAF inhibitor
- PembrolizumabSquamous cell cancer · Programmed cell death protein 1 inhibitor
- SunitinibRenal cell cancer · Macrophage colony stimulating factor receptor inhibitor
- CetuximabSquamous cell cancer · Epidermal growth factor receptor erbB1 inhibitor
- EverolimusRenal cell cancer · FK506-binding protein 1A inhibitor
- BevacizumabRenal cell cancer · Vascular endothelial growth factor A inhibitor
- NivolumabRenal cell cancer · Programmed cell death protein 1 inhibitor
- PazopanibRenal cell cancer · Macrophage colony stimulating factor receptor inhibitor
- AxitinibRenal cell cancer · Vascular endothelial growth factor receptor inhibitor
- IpilimumabRenal cell cancer · Cytotoxic T-lymphocyte protein 4 inhibitor
- LenvatinibRenal cell cancer · Vascular endothelial growth factor receptor inhibitor
- TremelimumabHepatocellular cancer · Cytotoxic T-lymphocyte protein 4 inhibitor
- CabozantinibRenal cell cancer · Vascular endothelial growth factor receptor 2 inhibitor
- ToripalimabNasopharyngeal cancer · Programmed cell death protein 1 antagonist
- TemsirolimusRenal cell cancer · FK506-binding protein 1A inhibitor
- PaclitaxelTubulin inhibitor
- BelzutifanRenal cell cancer · Endothelial PAS domain-containing protein 1 inhibitor
- CarboplatinOvarian epithelial cancer · DNA inhibitor
- AvelumabMerkel cell cancer · Programmed cell death 1 ligand 1 other
- DocetaxelSquamous cell cancer of head and neck · Tubulin inhibitor
- FluorouracilAdenocarcinoma · Thymidylate synthase inhibitor
- TivozanibRenal cell cancer · Vascular endothelial growth factor receptor inhibitor
- VandetanibMedullary cancer · Tyrosine-protein kinase SRC inhibitor
- PemigatinibCholangiocarcinoma · Fibroblast growth factor receptor 2 inhibitor
Phase 3 12 of 159
- CisplatinNasopharyngeal cancer · DNA inhibitor
- OxaliplatinHepatocellular cancer · DNA inhibitor
- LeucovorinHepatocellular cancer
- GemcitabinePancreatic ductal cancer · Ribonucleoside-diphosphate reductase RR1 inhibitor
- SintilimabHepatocellular cancer · Programmed cell death protein 1 antagonist
- CamrelizumabHepatocellular cancer · Programmed cell death protein 1 antagonist
- DurvalumabHepatocellular cancer · Programmed cell death 1 ligand 1 inhibitor
- RivoceranibHepatocellular cancer · Vascular endothelial growth factor receptor 2 inhibitor
- CapecitabineNasopharyngeal cancer · Thymidylate synthase inhibitor
- RegorafenibHepatocellular cancer · Tyrosine-protein kinase ABL inhibitor
- AldesleukinRenal cell cancer · Interleukin-2 receptor agonist
- CadonilimabHepatocellular cancer · Programmed cell death protein 1 inhibitor
Phase 2 12 of 374
- AdebrelimabHepatocellular cancer · Programmed cell death 1 ligand 1 inhibitor
- FludarabineHepatocellular cancer
- GalunisertibHepatocellular cancer · TGF-beta receptor type I inhibitor
- Nogapendekin alfaSquamous cell cancer
- FloxuridineCholangiocarcinoma · Thymidylate synthase inhibitor
- AlpelisibSquamous cell cancer · PI3-kinase p110-alpha subunit inhibitor
- BavituximabHepatocellular cancer · Phosphatidylserine inhibitor
- FirmonertinibAdenocarcinoma of lung · Epidermal growth factor receptor erbB1 inhibitor
- Bintrafusp alfaCholangiocarcinoma · Programmed cell death 1 ligand 1 binding agent
- Pegvorhyaluronidase alfaPancreatic ductal cancer · Hyaluronic acid hydrolytic enzyme
- GozetotideHepatocellular cancer · Diagnostic agent
- EndostatinNasopharyngeal cancer
Phase 1 or earlier 12 of 223
- GonadorelinExtramammary Paget disease · Gonadotropin-releasing hormone receptor agonist
- MapatumumabHepatocellular cancer · TRAIL receptor-1 agonist
- MogamulizumabC-C chemokine receptor type 4 cross-linking agent
- PepinemabSquamous cell cancer · Semaphorin-4D inhibitor
- FavezelimabRenal cell cancer · Lymphocyte activation gene 3 protein inhibitor
- MavorixaforRenal cell cancer · C-X-C chemokine receptor type 4 antagonist
- SelenomethionineRenal cell cancer
- AvadomideHepatocellular cancer
- Kisspeptin-10Extramammary Paget disease
- CesiumSquamous cell cancer
- C-188-9Squamous cell cancer
- AuranofinSquamous cell cancer
How its trials ended
8,789 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 1,972 whose ending is known, 27% met their primary endpoint, 9% missed it and 64% stopped early.
- Ongoing3,11635%
- Completed, result not reported2,28426%
- Status unknown1,41716%
- Stopped: other or unclear6187%
- Met its primary endpoint5286%
- Stopped: enrollment or feasibility3063%
- Missed its primary endpoint1852%
- Stopped: sponsor or business decision1742%
- Stopped: lack of efficacy901%
- Stopped: funding531%
- Stopped: safety18<1%
| Oct 22, 2026 | A phase 3, randomized, open-label, multicenter trial of amivantamab as sequential therapy following definitive, platinum-based, concurrent chemoradiotherapy,…Rybrevant (amivantamab0 | Johnson & Johnson | Pending |
| Oct 2, 2026 | A phase 2/3 multicenter, randomized, open-label study of ASP-1929 photoimmunotherapy in combination with pembrolizumab versus standard of care in the…ASP-1929 (cetuximab-IR700) | Rakuten Medical | Pending |
| Aug 6, 2026 | Rosetta RCC-208: a phase 1/2 open-label, multi-center, randomized study of pumitamig alone or in combination with ipilimumab or cabozantinib in participants…Pumitamig (BMS-986545; BNT327) / Ipilimumab / Cabozantinib | Bristol-Myers Squibb | Pending |
| Jun 29, 2026 | A phase 3, randomized, double-blind, study of belzutifan + zanzalintinib versus belzutifan + placebo in participants with advanced RCC who have progressed on…Belzutifan (MK-6482) / Zanzalintinib (XL092) | Merck & Co. (MSD) | Pending |
| Jun 26, 2026 | A phase 1/2, open-label trial to evaluate safety, immunogenicity, and anti-tumor activity of VB10.16 in combination with pembrolizumab in patients with…VB10.16 (abipapogene suvaplasmid) / Pembrolizumab | Nykode Therapeutics Asa | Pending |
| Jun 10, 2026 | A phase 3, randomized, open-label study of belzutifan + zanzalintinib versus cabozantinib in participants with advanced RCC who experienced disease recurrence…Belzutifan (MK-6482) / Zanzalintinib (XL092) | Merck & Co. (MSD) | Ongoing |
| Apr 23, 2026 | A phase 1 first-in-human, open-label study evaluating the safety, pharmacokinetics, and efficacy of ABBV-711 as a monotherapy or in combination with…ABBV-711 / Budigalimab (ABBV-181) | AbbVie | Ongoing |
| Mar 4, 2026 | A multicenter, open-label, phase 3 extension study to evaluate the longterm efficacy and safety in participants who are currently on treatment in a belzutifan…Belzutifan / Lenvatinib | Merck & Co. (MSD) | Ongoing |
| Feb 26, 2026 | A randomized, open-label phase 3 study of azenosertib versus investigator’s choice of chemotherapy in platinum resistant high-grade serous ovarian, primary…Azenosertib | K-Group Beta, Inc. | Pending |
| Dec 19, 2025 | Capecitabine prior to tumor resection in entoncology (CAPTURE)Capecitabine | Research Institute of The McGill University Health Centre | Pending |
| May 15, 2025 | ZynyzIn combination with carboplatin and paclitaxel, for the first-line treatment of adult patients with inoperable locally recurrent or… | Incyte Corporation | Approved |
| Apr 23, 2025 | Penpulimab-kcqxIn combination with either cisplatin or carboplatin and gemcitabine, for the first-line treatment of adults with recurrent or metastatic… | Akeso Biopharma Co., Ltd. | Approved |
| Apr 11, 2025 | OpdivoIn combination with ipilimumab, for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma… | Bristol-Myers Squibb Company | Approved |
| Mar 3, 2025 | TevimbraIn combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or metastatic esophageal… | BeOne Medicines USA, Inc. | Approved |
| Mar 13, 2024 | TevimbraAs a single agent, for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma after prior… | BeOne Medicines USA, Inc. | Approved |
| Jan 25, 2024 | KeytrudaTreatment of patients with hepatocellular carcinoma (HCC) secondary to hepatitis B who have received prior systemic therapy other than a… | MSD International Business GmbH | Approved |
| Oct 31, 2023 | KeytrudaIn combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract… | MSD International Business GmbH | Approved |
| Oct 27, 2023 | LoqtorziIn combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or with recurrent, locally advanced… | Coherus BioSciences, Inc. | Approved |
| Mar 22, 2023 | ZynyzTreatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC) | Incyte Corporation | Approved |
| Oct 21, 2022 | ImfinziIn combination with tremelimumab-actl for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC) | AstraZeneca Pharmaceuticals LP | Approved |
| Oct 21, 2022 | ImjudoIn combination with durvalumab for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC) | AstraZeneca Pharmaceuticals LP | Approved |
| May 27, 2022 | OpdivoIn combination with ipilimumab, for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous… | Bristol-Myers Squibb Company | Approved |
| May 27, 2022 | OpdivoIn combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with… | Bristol-Myers Squibb Company | Approved |
| Sep 17, 2021 | CabometyxTreatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC)… | Exelixis, Inc. | Approved |
| Aug 13, 2021 | WeliregTreatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central… | Merck Sharp & Dohme, LLC | Approved |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA